639 related articles for article (PubMed ID: 33714688)
1. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Kang JH; Bluestone JA; Young A
Trends Immunol; 2021 Apr; 42(4):293-311. PubMed ID: 33714688
[TBL] [Abstract][Full Text] [Related]
2. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Tang H; Guan M; Sun Z; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
[TBL] [Abstract][Full Text] [Related]
3. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
4. Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels.
Zhao N; Jiang A; Shang X; Zhao F; Wang R; Fu X; Ruan Z; Liang X; Tian T; Yao Y; Li C
J Immunother; 2023 Oct; 46(8):310-322. PubMed ID: 37335173
[TBL] [Abstract][Full Text] [Related]
5. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.
Jia XH; Geng LY; Jiang PP; Xu H; Nan KJ; Yao Y; Jiang LL; Sun H; Qin TJ; Guo H
J Exp Clin Cancer Res; 2020 Dec; 39(1):284. PubMed ID: 33317597
[TBL] [Abstract][Full Text] [Related]
6. Stocking the toolbox-Using preclinical models to understand the development and treatment of immune checkpoint inhibitor-induced immune-related adverse events.
Cina ML; Venegas J; Young A
Immunol Rev; 2023 Sep; 318(1):110-137. PubMed ID: 37565407
[TBL] [Abstract][Full Text] [Related]
7. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J; Murphy C; Atkins MB; Brahmer JR; Champiat S; Feltquate D; Krug LM; Moslehi J; Pietanza MC; Riemer J; Robert C; Sharon E; Suarez-Almazor ME; Suresh K; Turner M; Weber J; Cappelli LC
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001909
[TBL] [Abstract][Full Text] [Related]
8. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy.
Kubo T; Hirohashi Y; Tsukahara T; Kanaseki T; Murata K; Morita R; Torigoe T
Immunol Med; 2022 Jun; 45(2):108-118. PubMed ID: 34542015
[TBL] [Abstract][Full Text] [Related]
9. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Jacoberger-Foissac C; Blake SJ; Liu J; McDonald E; Triscott H; Nakamura K; Smyth MJ; Teng MW
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199513
[TBL] [Abstract][Full Text] [Related]
10. The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors.
Wang M; Zhai X; Li J; Guan J; Xu S; Li Y; Zhu H
Front Immunol; 2021; 12():670391. PubMed ID: 34367136
[TBL] [Abstract][Full Text] [Related]
11.
Hamada K; Isobe J; Hattori K; Hosonuma M; Baba Y; Murayama M; Narikawa Y; Toyoda H; Funayama E; Tajima K; Shida M; Hirasawa Y; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Sambe T; Tsuji M; Wada S; Kiuchi Y; Kobayashi S; Kuramasu A; Horiike A; Kim YG; Tsunoda T; Yoshimura K
Front Immunol; 2023; 14():1164724. PubMed ID: 37207204
[TBL] [Abstract][Full Text] [Related]
12. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach.
de La Rochefoucauld J; Noël N; Lambotte O
Intern Emerg Med; 2020 Jun; 15(4):587-598. PubMed ID: 32144552
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
Khan OF; Monzon J
Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
[TBL] [Abstract][Full Text] [Related]
14. Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Immunotherapy; 2020 Nov; 12(16):1183-1193. PubMed ID: 32878511
[No Abstract] [Full Text] [Related]
15. Tying Small Changes to Large Outcomes: The Cautious Promise in Incorporating the Microbiome into Immunotherapy.
Chau J; Zhang J
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360663
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors.
Lee DJ; Lee HJ; Farmer JR; Reynolds KL
Curr Cardiol Rep; 2021 Jul; 23(8):98. PubMed ID: 34196833
[TBL] [Abstract][Full Text] [Related]
17. Use of glucocorticoids in the management of immunotherapy-related adverse effects.
Wang H; Zhou J; Guo X; Li Y; Duan L; Si X; Zhang L
Thorac Cancer; 2020 Oct; 11(10):3047-3052. PubMed ID: 32893490
[TBL] [Abstract][Full Text] [Related]
18. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
